MedTrace Logo

A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

NCT05393063 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-05-26

No results posted yet for this study

Summary

This study is to characterize the safety, tolerability and anti-tumor activity of AK127 as a single agent in adult subjects with advanced solid tumor malignancies.

Conditions

Interventions

DRUG

AK127

Subjects will receive AK127 by intravenous administration（administered on Day 1 of each cycle, Q3W）

Sponsors & Collaborators

Principal Investigators

  • Shun Lu, Chief doctor · Shanghai Chest Hospital

  • Yun Fan, Chief doctor · Zhejiang Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2023-06-30
Completion
2024-06-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05393063 on ClinicalTrials.gov